ANL vs PRE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Adlai Nortye Ltd. (ANL) exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health—alongside a dangerously high Debt/Equity ratio of 5.63 and negative ROE of -138.98%. The company shows no profitability, with zero margins and negative earnings, while its Price/Book ratio of 36.98 suggests extreme overvaluation relative to book value. Despite a recent 1Y return of +247.2%, this surge appears speculative rather than fundamentals-driven, with no analyst consensus and no dividend or cash flow generation. The absence of key valuation metrics and the lack of sustainable growth signals make the current price unsustainable.
Prenetics Global Limited presents a high-risk, high-reward profile characterized by explosive revenue growth (248.6% YoY) contrasted with deep operational losses. The Piotroski F-Score of 4/9 indicates a stable but not strong financial position, while the absence of an Altman Z-Score is mitigated by an exceptionally low Debt/Equity ratio (0.01) and strong liquidity (Current Ratio 3.01). While analysts maintain a 'strong_buy' rating with a target of $31.25, the 0/100 technical trend and low insider sentiment (40/100) suggest significant near-term headwinds despite the long-term growth trajectory.
Compare Another Pair
Related Comparisons
ANL vs PRE: Head-to-Head Comparison
This page compares Adlai Nortye Ltd. (ANL) and Prenetics Global Limited (PRE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.